SrasV1, PubMed, Checkpoint, bibRecord, 003299

Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.

Identifieur interne : 003299 ( PubMed/Checkpoint ); précédent : 003298; suivant : 003300

Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.

Auteurs : Yossef Kliger [Israël] ; Erez Y. Levanon

Source :

BMC microbiology [ 1471-2180 ] ; 2003.

RBID : pubmed:14499001

Descripteurs français

KwdFr :
- Agents antiVIH (pharmacologie), Antiviraux (pharmacologie), Conception de médicament, Conformation des protéines, Données de séquences moléculaires, Fragments peptidiques (pharmacologie), Protéine d'enveloppe gp41 du VIH (pharmacologie), Protéines de fusion virale (), Protéines de fusion virale (génétique), Protéines de fusion virale (métabolisme), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), Virus du SRAS ().
MESH :
- génétique : Protéines de fusion virale.
- métabolisme : Protéines de fusion virale.
- pharmacologie : Agents antiVIH, Antiviraux, Fragments peptidiques, Protéine d'enveloppe gp41 du VIH.
- Conception de médicament, Conformation des protéines, Données de séquences moléculaires, Protéines de fusion virale, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Virus du SRAS.

English descriptors

KwdEn :
- Anti-HIV Agents (pharmacology), Antiviral Agents (pharmacology), Drug Design, Enfuvirtide, HIV Envelope Protein gp41 (pharmacology), HIV-1 (chemistry), HIV-1 (drug effects), Molecular Sequence Data, Peptide Fragments (pharmacology), Protein Conformation, SARS Virus (chemistry), SARS Virus (drug effects), Viral Fusion Proteins (chemistry), Viral Fusion Proteins (genetics), Viral Fusion Proteins (metabolism).
MESH :
- chemical , chemistry : Viral Fusion Proteins.
- chemical , genetics : Viral Fusion Proteins.
- chemical , metabolism : Viral Fusion Proteins.
- chemical , pharmacology : Anti-HIV Agents, Antiviral Agents, HIV Envelope Protein gp41, Peptide Fragments.
- chemistry : HIV-1, SARS Virus.
- drug effects : HIV-1, SARS Virus.
- Drug Design, Enfuvirtide, Molecular Sequence Data, Protein Conformation.

Abstract

Severe acute respiratory syndrome (SARS) is a febrile respiratory illness. The disease has been etiologically linked to a novel coronavirus that has been named the SARS-associated coronavirus (SARS-CoV), whose genome was recently sequenced. Since it is a member of the Coronaviridae, its spike protein (S2) is believed to play a central role in viral entry by facilitating fusion between the viral and host cell membranes. The protein responsible for viral-induced membrane fusion of HIV-1 (gp41) differs in length, and has no sequence homology with S2.

DOI: 10.1186/1471-2180-3-20
PubMed: 14499001

Affiliations:

Israël

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 003182
to stream PubMed, to step Curation: 003182

Links to Exploration step

pubmed:14499001

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.</title>
<author><name sortKey="Kliger, Yossef" sort="Kliger, Yossef" uniqKey="Kliger Y" first="Yossef" last="Kliger">Yossef Kliger</name>
<affiliation wicri:level="1"><nlm:affiliation>Compugen LTD, Tel Aviv, 69512, Israel. kliger@compugen.co.il</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Compugen LTD, Tel Aviv, 69512</wicri:regionArea>
<wicri:noRegion>69512</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Levanon, Erez Y" sort="Levanon, Erez Y" uniqKey="Levanon E" first="Erez Y" last="Levanon">Erez Y. Levanon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:14499001</idno>
<idno type="pmid">14499001</idno>
<idno type="doi">10.1186/1471-2180-3-20</idno>
<idno type="wicri:Area/PubMed/Corpus">003182</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003182</idno>
<idno type="wicri:Area/PubMed/Curation">003182</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003182</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003299</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003299</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.</title>
<author><name sortKey="Kliger, Yossef" sort="Kliger, Yossef" uniqKey="Kliger Y" first="Yossef" last="Kliger">Yossef Kliger</name>
<affiliation wicri:level="1"><nlm:affiliation>Compugen LTD, Tel Aviv, 69512, Israel. kliger@compugen.co.il</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Compugen LTD, Tel Aviv, 69512</wicri:regionArea>
<wicri:noRegion>69512</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Levanon, Erez Y" sort="Levanon, Erez Y" uniqKey="Levanon E" first="Erez Y" last="Levanon">Erez Y. Levanon</name>
</author>
</analytic>
<series><title level="j">BMC microbiology</title>
<idno type="eISSN">1471-2180</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-HIV Agents (pharmacology)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Drug Design</term>
<term>Enfuvirtide</term>
<term>HIV Envelope Protein gp41 (pharmacology)</term>
<term>HIV-1 (chemistry)</term>
<term>HIV-1 (drug effects)</term>
<term>Molecular Sequence Data</term>
<term>Peptide Fragments (pharmacology)</term>
<term>Protein Conformation</term>
<term>SARS Virus (chemistry)</term>
<term>SARS Virus (drug effects)</term>
<term>Viral Fusion Proteins (chemistry)</term>
<term>Viral Fusion Proteins (genetics)</term>
<term>Viral Fusion Proteins (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH (pharmacologie)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Conception de médicament</term>
<term>Conformation des protéines</term>
<term>Données de séquences moléculaires</term>
<term>Fragments peptidiques (pharmacologie)</term>
<term>Protéine d'enveloppe gp41 du VIH (pharmacologie)</term>
<term>Protéines de fusion virale ()</term>
<term>Protéines de fusion virale (génétique)</term>
<term>Protéines de fusion virale (métabolisme)</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term>
<term>Virus du SRAS ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Viral Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Viral Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Viral Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Antiviral Agents</term>
<term>HIV Envelope Protein gp41</term>
<term>Peptide Fragments</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>HIV-1</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines de fusion virale</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Protéines de fusion virale</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiVIH</term>
<term>Antiviraux</term>
<term>Fragments peptidiques</term>
<term>Protéine d'enveloppe gp41 du VIH</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Design</term>
<term>Enfuvirtide</term>
<term>Molecular Sequence Data</term>
<term>Protein Conformation</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Conception de médicament</term>
<term>Conformation des protéines</term>
<term>Données de séquences moléculaires</term>
<term>Protéines de fusion virale</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a febrile respiratory illness. The disease has been etiologically linked to a novel coronavirus that has been named the SARS-associated coronavirus (SARS-CoV), whose genome was recently sequenced. Since it is a member of the Coronaviridae, its spike protein (S2) is believed to play a central role in viral entry by facilitating fusion between the viral and host cell membranes. The protein responsible for viral-induced membrane fusion of HIV-1 (gp41) differs in length, and has no sequence homology with S2.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14499001</PMID>
<DateCompleted><Year>2004</Year>
<Month>02</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2180</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>3</Volume>
<PubDate><Year>2003</Year>
<Month>Sep</Month>
<Day>21</Day>
</PubDate>
</JournalIssue>
<Title>BMC microbiology</Title>
<ISOAbbreviation>BMC Microbiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.</ArticleTitle>
<Pagination><MedlinePgn>20</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Severe acute respiratory syndrome (SARS) is a febrile respiratory illness. The disease has been etiologically linked to a novel coronavirus that has been named the SARS-associated coronavirus (SARS-CoV), whose genome was recently sequenced. Since it is a member of the Coronaviridae, its spike protein (S2) is believed to play a central role in viral entry by facilitating fusion between the viral and host cell membranes. The protein responsible for viral-induced membrane fusion of HIV-1 (gp41) differs in length, and has no sequence homology with S2.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Sequence analysis reveals that the two viral proteins share the sequence motifs that construct their active conformation. These include (1) an N-terminal leucine/isoleucine zipper-like sequence, and (2) a C-terminal heptad repeat located upstream of (3) an aromatic residue-rich region juxtaposed to the (4) transmembrane segment.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study points to a similar mode of action for the two viral proteins, suggesting that anti-viral strategy that targets the viral-induced membrane fusion step can be adopted from HIV-1 to SARS-CoV. Recently the FDA approved Enfuvirtide, a synthetic peptide corresponding to the C-terminal heptad repeat of HIV-1 gp41, as an anti-AIDS agent. Enfuvirtide and C34, another anti HIV-1 peptide, exert their inhibitory activity by binding to a leucine/isoleucine zipper-like sequence in gp41, thus inhibiting a conformational change of gp41 required for its activation. We suggest that peptides corresponding to the C-terminal heptad repeat of the S2 protein may serve as inhibitors for SARS-CoV entry.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kliger</LastName>
<ForeName>Yossef</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Compugen LTD, Tel Aviv, 69512, Israel. kliger@compugen.co.il</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Levanon</LastName>
<ForeName>Erez Y</ForeName>
<Initials>EY</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>RefSeq</DataBankName>
<AccessionNumberList><AccessionNumber>NC_004718</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2003</Year>
<Month>09</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>BMC Microbiol</MedlineTA>
<NlmUniqueID>100966981</NlmUniqueID>
<ISSNLinking>1471-2180</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015700">HIV Envelope Protein gp41</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014760">Viral Fusion Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C407149">peptide C34</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>19OWO1T3ZE</RegistryNumber>
<NameOfSubstance UI="D000077560">Enfuvirtide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000077560" MajorTopicYN="N">Enfuvirtide</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015700" MajorTopicYN="N">HIV Envelope Protein gp41</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014760" MajorTopicYN="N">Viral Fusion Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year>
<Month>07</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2003</Year>
<Month>09</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2003</Year>
<Month>9</Month>
<Day>23</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>2</Month>
<Day>26</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2003</Year>
<Month>9</Month>
<Day>23</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">14499001</ArticleId>
<ArticleId IdType="doi">10.1186/1471-2180-3-20</ArticleId>
<ArticleId IdType="pii">1471-2180-3-20</ArticleId>
<ArticleId IdType="pmc">PMC222911</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Biol Chem. 2001 Jan 12;276(2):1391-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11027678</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEBS Lett. 2000 Dec 29;487(2):185-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11150506</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Mar;77(6):3724-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12610147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2003 May;2(5):345-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12755128</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 1970 Mar;48(3):443-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5420325</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 1990 Oct 5;215(3):403-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2231712</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AIDS Res Hum Retroviruses. 1993 Nov;9(11):1051-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8312047</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9770-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7937889</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 1995 Nov 15;14(22):5524-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8521809</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Struct Biol. 1995 Dec;2(12):1075-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8846219</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8700906</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 1997 Apr 18;89(2):263-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9108481</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1997 May 22;387(6631):426-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9163431</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 1998 May 29;93(5):681-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9630213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15613-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9861018</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1999 Mar;73(3):2469-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9971832</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 1999 Jul 30;290(5):1031-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10438601</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2000 Jan;6(1):35-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10613821</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioinformatics. 2001 Sep;17(9):849-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11590105</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Israël</li>
</country>
</list>
<tree><noCountry><name sortKey="Levanon, Erez Y" sort="Levanon, Erez Y" uniqKey="Levanon E" first="Erez Y" last="Levanon">Erez Y. Levanon</name>
</noCountry>
<country name="Israël"><noRegion><name sortKey="Kliger, Yossef" sort="Kliger, Yossef" uniqKey="Kliger Y" first="Yossef" last="Kliger">Yossef Kliger</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003299 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003299 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:14499001
   |texte=   Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:14499001" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.

Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki